---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Pharmacokinetics"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Pharmacokinetics. Topics: Dose proportionality, half-life, and renal clearance in healthy adults; Steady-state exposure at 45 mg once daily and exposure margin at 120 mg once daily; Food effect in the first-in-human study; Relative bioavailability and food effect of a test tablet formulation. 4 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/pharmacokinetics"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Pharmacokinetics

<a id="heading-2.1.2.6.3"></a>

## 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

### Dose proportionality, half-life, and renal clearance in healthy adults

> “The PK of inaxaplin was generally dose proportional, and the variability in PK parameters was generally low and did not appear to change across the dose range (online Table S1).”
> “Half-life was consistent across both studies ranging from approximately 13.3 to 22.9 h, which supports once daily dosing (online Table S1).”
> “Renal clearance was a minor excretion pathway for inaxaplin”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-2.1.2.6.3-2"></a>

### Steady-state exposure at 45 mg once daily and exposure margin at 120 mg once daily

> “Preliminary PK analysis demonstrated that the mean (CV%) AUC0-24h,ss achieved at this dose was 50.1 (27.5%) µg*h/mL, providing an approximately 3.8-fold exposure margin over the 45 mg qd clinical dose with a mean (CV%) AUC0-24h,ss of 13.3 (21.5%) µg*h/mL (Study 001).”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-2.1.2.6.3-3"></a>

### Food effect in the first-in-human study

> “Removed the requirement to fast before and after dosing, based on data from Study VX18-147-001 showing no food effect.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-2.1.2.6.3-4"></a>

### Relative bioavailability and food effect of a test tablet formulation

> “The purpose of the study is to evaluate the relative bioavailability (BA) and the effect of food on the pharmacokinetics (PK), and the safety and tolerability of VX-147 test tablet formulation.”
> “Participants will receive VX-147 reference tablet under fasted condition in Treatment Period 1, then VX-147 test tablet under fed condition in Treatment Period 2, and VX-147 test tablet under fasted condition in Treatment Period 3.”

Source: [ClinicalTrials.gov NCT05955872](https://clinicaltrials.gov/study/NCT05955872)

Additional sources: [ClinicalTrials.gov NCT04340362](https://clinicaltrials.gov/study/NCT04340362)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
